Brii Biosciences Limited

Quick facts

Phase 2 pipeline

• BRII-179
• BRII-296 · Infectious disease
  BRII-296 is a monoclonal antibody that targets the SARS-CoV-2 spike protein.
• BRII-835 · Infectious disease
  BRII-835 is a monoclonal antibody that targets the SARS-CoV-2 spike protein.
• VIR-2218

Phase 1 pipeline

• BRII-297

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Brii Biosciences Limited portfolio CI brief
• Brii Biosciences Limited pipeline updates RSS